AAPL   380.02 (-0.71%)
AMZN   3,157.98 (-0.77%)
NVDA   417.40 (-0.70%)
CGC   16.36 (+2.12%)
BABA   257.13 (-1.70%)
TSLA   1,382.07 (-0.88%)
AMD   56.59 (-1.17%)
T   29.64 (+0.34%)
F   5.85 (+0.00%)
GILD   75.87 (+1.55%)
DIS   117.14 (+0.27%)
BAC   23.12 (+1.54%)
NFLX   520.30 (+2.47%)
BA   173.14 (-0.08%)
AAPL   380.02 (-0.71%)
AMZN   3,157.98 (-0.77%)
NVDA   417.40 (-0.70%)
CGC   16.36 (+2.12%)
BABA   257.13 (-1.70%)
TSLA   1,382.07 (-0.88%)
AMD   56.59 (-1.17%)
T   29.64 (+0.34%)
F   5.85 (+0.00%)
GILD   75.87 (+1.55%)
DIS   117.14 (+0.27%)
BAC   23.12 (+1.54%)
NFLX   520.30 (+2.47%)
BA   173.14 (-0.08%)
AAPL   380.02 (-0.71%)
AMZN   3,157.98 (-0.77%)
NVDA   417.40 (-0.70%)
CGC   16.36 (+2.12%)
BABA   257.13 (-1.70%)
TSLA   1,382.07 (-0.88%)
AMD   56.59 (-1.17%)
T   29.64 (+0.34%)
F   5.85 (+0.00%)
GILD   75.87 (+1.55%)
DIS   117.14 (+0.27%)
BAC   23.12 (+1.54%)
NFLX   520.30 (+2.47%)
BA   173.14 (-0.08%)
AAPL   380.02 (-0.71%)
AMZN   3,157.98 (-0.77%)
NVDA   417.40 (-0.70%)
CGC   16.36 (+2.12%)
BABA   257.13 (-1.70%)
TSLA   1,382.07 (-0.88%)
AMD   56.59 (-1.17%)
T   29.64 (+0.34%)
F   5.85 (+0.00%)
GILD   75.87 (+1.55%)
DIS   117.14 (+0.27%)
BAC   23.12 (+1.54%)
NFLX   520.30 (+2.47%)
BA   173.14 (-0.08%)
Log in

NASDAQ:KNSAKiniksa Pharmaceuticals Stock Price, Forecast & News

$23.31
+0.27 (+1.17 %)
(As of 07/10/2020 10:06 AM ET)
Add
Compare
Today's Range
$23.04
Now: $23.31
$23.62
50-Day Range
$20.64
MA: $22.71
$26.00
52-Week Range
$5.01
Now: $23.31
$28.67
Volume535 shs
Average Volume316,265 shs
Market Capitalization$1.39 billion
P/E RatioN/A
Dividend YieldN/A
Beta0.01
Kiniksa Pharmaceuticals, Ltd., a clinical-stage biopharmaceutical company, focuses on the discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need worldwide. Its clinical-stage product candidates include Rilonacept, which is in Phase II clinical trials for the treatment of recurrent pericarditis, an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody for the treatment of giant cell arteritis; and KPL-716, a monoclonal antibody, which is in Phase 1a/1b clinical trial for the treatment of prurigo nodularis and atopic dermatitis. The company's preclinical product candidates comprise KPL-404, a monoclonal antibody inhibitor of the CD40 co-stimulatory receptor; and KPL-045, a monoclonal antibody inhibitor of the CD30 ligand co-stimulatory molecule. Kiniksa Pharmaceuticals, Ltd. was founded in 2015 and is based in Hamilton, Bermuda.
Read More
Kiniksa Pharmaceuticals logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.38 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:KNSA
CUSIPN/A
CIKN/A
Phone44-80-8189-6257

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$4.10 per share

Profitability

Net Income$-161,870,000.00

Miscellaneous

Employees111
Market Cap$1.39 billion
Next Earnings Date8/10/2020 (Estimated)
OptionableNot Optionable

Receive KNSA News and Ratings via Email

Sign-up to receive the latest news and ratings for KNSA and its competitors with MarketBeat's FREE daily newsletter.

Kiniksa Pharmaceuticals (NASDAQ:KNSA) Frequently Asked Questions

How has Kiniksa Pharmaceuticals' stock been impacted by COVID-19 (Coronavirus)?

Kiniksa Pharmaceuticals' stock was trading at $16.10 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, KNSA shares have increased by 44.8% and is now trading at $23.31. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Kiniksa Pharmaceuticals?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Kiniksa Pharmaceuticals in the last year. There are currently 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Kiniksa Pharmaceuticals.

When is Kiniksa Pharmaceuticals' next earnings date?

Kiniksa Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Monday, August 10th 2020. View our earnings forecast for Kiniksa Pharmaceuticals.

How were Kiniksa Pharmaceuticals' earnings last quarter?

Kiniksa Pharmaceuticals Ltd (NASDAQ:KNSA) released its quarterly earnings data on Tuesday, April, 28th. The company reported ($0.48) EPS for the quarter, beating the Zacks' consensus estimate of ($0.63) by $0.15. View Kiniksa Pharmaceuticals' earnings history.

What price target have analysts set for KNSA?

6 Wall Street analysts have issued 12 month target prices for Kiniksa Pharmaceuticals' shares. Their forecasts range from $24.00 to $40.00. On average, they anticipate Kiniksa Pharmaceuticals' stock price to reach $32.50 in the next twelve months. This suggests a possible upside of 39.4% from the stock's current price. View analysts' price targets for Kiniksa Pharmaceuticals.

Has Kiniksa Pharmaceuticals been receiving favorable news coverage?

Media headlines about KNSA stock have been trending somewhat positive recently, according to InfoTrie. InfoTrie identifies positive and negative media coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Kiniksa Pharmaceuticals earned a daily sentiment score of 1.8 on InfoTrie's scale. They also gave news headlines about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the company's share price in the next several days. View the latest news about Kiniksa Pharmaceuticals.

Who are some of Kiniksa Pharmaceuticals' key competitors?

What other stocks do shareholders of Kiniksa Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Kiniksa Pharmaceuticals investors own include Crispr Therapeutics (CRSP), Exelixis (EXEL), AbbVie (ABBV), Gilead Sciences (GILD), VBI Vaccines (VBIV), Vanda Pharmaceuticals (VNDA), Agile Therapeutics (AGRX), Clovis Oncology (CLVS), Dicerna Pharmaceuticals (DRNA) and ImmunoGen (IMGN).

Who are Kiniksa Pharmaceuticals' key executives?

Kiniksa Pharmaceuticals' management team includes the following people:
  • Mr. Sanj K. Patel, CEO & Chairman (Age 49)
  • Mr. Stephen Mahoney, Pres & COO (Age 47)
  • Dr. John F. Paolini, Chief Medical Officer (Age 53)
  • Mr. Chris Heberlig, Exec. VP & CFO (Age 43)
  • Mark Ragosa C.F.A., VP of Investor Relations

When did Kiniksa Pharmaceuticals IPO?

(KNSA) raised $126 million in an IPO on Thursday, May 24th 2018. The company issued 7,000,000 shares at $17.00-$19.00 per share. Goldman Sachs and J.P. Morgan acted as the underwriters for the IPO and JMP Securities and Wedbush PacGrow were co-managers.

What is Kiniksa Pharmaceuticals' stock symbol?

Kiniksa Pharmaceuticals trades on the NASDAQ under the ticker symbol "KNSA."

How do I buy shares of Kiniksa Pharmaceuticals?

Shares of KNSA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Kiniksa Pharmaceuticals' stock price today?

One share of KNSA stock can currently be purchased for approximately $23.31.

How big of a company is Kiniksa Pharmaceuticals?

Kiniksa Pharmaceuticals has a market capitalization of $1.39 billion. The company earns $-161,870,000.00 in net income (profit) each year or ($2.99) on an earnings per share basis. Kiniksa Pharmaceuticals employs 111 workers across the globe.

What is Kiniksa Pharmaceuticals' official website?

The official website for Kiniksa Pharmaceuticals is www.kiniksa.com.

How can I contact Kiniksa Pharmaceuticals?

Kiniksa Pharmaceuticals' mailing address is CLARENDON HOUSE 2 CHURCH STREET, HAMILTON D0, HM11. The company can be reached via phone at 44-80-8189-6257 or via email at [email protected]

This page was last updated on 7/10/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

  • Best-in-Class Portfolio Monitoring

    View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.

  • Stock Ideas and Recommendations

    Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.

  • Advanced Stock Screeners and Research Tools

    Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.